.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,576,328

« Back to Dashboard

Claims for Patent: 5,576,328

Title: Method for the secondary prevention of ischemic events
Abstract:The invention relates to a new method for the secondary prevention of ischemic events comprising administering to a man in need thereof a therapeutically effective amount of a compound selected from clopidogrel and its pharmaceutically acceptable acid addition salts in association with a pharmaceutically acceptable carrier.
Inventor(s): Herbert; Jean-Marc (Tournefeuille, FR), Frehel; Daniel (Toulouse, FR), Bernat; Andr e (Cugnaux, FR), Badorc; Alain (Roquettes, FR), Savi; Pierre (Seysses, FR), Delebass ee; Denis (Goyrans, FR), Kieffer; Gilles (Montpellier, FR), Defreyn; Ghislain (Eaunes, FR), Maffrand; Jean-Pierre (Portet/Garonne, FR)
Assignee: Elf Sanofi (Paris, FR)
Application Number:08/190,332
Patent Claims: 1. A method for preventing the occurrence of a secondary ischemic event comprising administering to a patient who has suffered a primary ischemic event a therapeutically effective amount of a compound selected from clopidogrel and a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier.

2. The method according to claim 1, wherein the primary and/or secondary ischemic event is a myocardial infarction.

3. The method according to claim 1, wherein the primary and/or secondary ischemic event is unstable or stable angina.

4. The method according to claim 1, wherein the primary and/or secondary ischemic event is acute reocclusion after percutaneous transluminal coronary angioplasty.

5. The method according to claim 1, wherein the primary and/or secondary ischemic event is restenosis.

6. The method according to claim 1, wherein the primary and/or secondary ischemic event is thrombotic stroke.

7. The method according to claim 1, wherein the primary and/or secondary ischemic event is a transient ischemic attack.

8. The method according to claim 1, wherein the primary and/or secondary ischemic event is reversible ischemic neurological deficit.

9. The method according to claim 1, wherein the primary or secondary ischemic event is intermittent claudication.

10. A method according to claim 1, in which said acid addition salt is the hydrogen-sulfate.

11. A method according to claim 1, wherein the route of administration of the compound is either the oral route or the intravenous route.

12. A method according to claim 1, wherein the compound is orally administered in a daily amount varying from 25 to 600 mg.

13. A method according to claim 1, wherein the compound is orally administered in a daily amount of 75 mg.

14. A method according to claim 1, wherein the administration of the compound is concomitant to the administration of aprotinin.

15. The method according to claim 1, wherein said compound is selected from clopidogrel and clopidogrel hydrogen-sulfate said compound being administered in combination with a thrombolytic agent.

16. The method according to claim 15, wherein the thrombolytic agent is streptokinase.

17. The method of claim 15, wherein the compound is clopidogrel hydrogen-sulfate.

18. The method of claim 14, wherein the compound is clopidogrel hydrogen-sulfate.

19. The method of claim 1, wherein the compound is clopidogrel hydrogen-sulfate.

20. A method of preventing ischemia-induced secondary ischemia comprising administering to a patient who has suffered an ischemic event a therapeutically effective amount of a compound selected from clopidogrel and a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc